Literature DB >> 9068079

Physiologic and molecular characterization of the role of nitric oxide in hemorrhagic shock: evidence that type II nitric oxide synthase does not regulate vascular decompensation.

E Kelly1, N S Shah, N N Morgan, S C Watkins, A B Peitzman, T R Billiar.   

Abstract

To determine the role of nitric oxide (NO) in decompensated and irreversible hemorrhagic shock, rats were subjected to hemorrhagic shock (HS) for 3 or 5 h. Lung, liver, and plasma samples were studied for evidence of NO formation using Northern analysis and immunohistochemistry for Type II NOS, as well as measurement of plasma nitrite/nitrate, cyclic GMP, and nitrosylated hemoglobin levels. Comparisons were made with similarly instrumented time-matched sham rats. Type II NOS mRNA and protein were detectable in lung and liver only in the irreversible phase of HS (5 h). A large accumulation of nitrosylated hemoglobin and nitrite/nitrate appeared in the irreversible phase. Significant accumulation of cyclic GMP or nitrite/nitrate was not detectable in the decompensation phase. Despite the hemodynamic decompensation at 3 h of HS, Type II NOS mRNA and protein expression, as well as NO metabolites were not elevated. To assess whether NO plays a physiologically significant role in decompensation, rats in the decompensation phase and sham animals were subjected to nonspecific NOS inhibition. Both groups displayed a similar magnitude and duration of blood pressure elevation. Hemodynamic decompensation in HS is not mediated by Type II NOS induction. NO production increases only after prolonged HS; significant NO production is observed only in severe, irreversible HS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9068079     DOI: 10.1097/00024382-199703000-00001

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  8 in total

1.  The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure.

Authors:  Frederick A Moore; Ernest E Moore; Timothy R Billiar; Yoram Vodovotz; Anirban Banerjee; Lyle L Moldawer
Journal:  J Trauma Acute Care Surg       Date:  2017-09       Impact factor: 3.313

2.  Intestinal expressions of eNOSmRNA and iNOSmRNA in rats with acute liver failure.

Authors:  J M Qin; Y D Zhang
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study.

Authors:  Wei Chong; Yongqing Li; Baoling Liu; Zhengcai Liu; Ting Zhao; Diane R Wonsey; Changmin Chen; George C Velmahos; Marc A deMoya; David R King; Andrew L Kung; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2012-02       Impact factor: 3.313

4.  Inducible nitric oxide synthase contributes to immune dysfunction following trauma.

Authors:  Sophie S Darwiche; Roman Pfeifer; Christoph Menzel; Xiangcai Ruan; Marcus Hoffman; Changchun Cai; R Savanh Chanthaphavong; Patricia Loughran; Bruce R Pitt; Rosemary Hoffman; Hans-Christoph Pape; Timothy R Billiar
Journal:  Shock       Date:  2012-11       Impact factor: 3.454

5.  Pancreatic digestive enzyme blockade in the small intestine prevents insulin resistance in hemorrhagic shock.

Authors:  Frank A DeLano; Geert W Schmid-Schönbein
Journal:  Shock       Date:  2014-01       Impact factor: 3.454

Review 6.  Role of nitric oxide in inflammation and tissue injury during endotoxemia and hemorrhagic shock.

Authors:  N S Shah; T R Billiar
Journal:  Environ Health Perspect       Date:  1998-10       Impact factor: 9.031

7.  Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock.

Authors:  C Hierholzer; B Harbrecht; J M Menezes; J Kane; J MacMicking; C F Nathan; A B Peitzman; T R Billiar; D J Tweardy
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

8.  Preservation of myocardial contractile function by aminoguanidine, a nitric oxide synthase inhibitors, in a rat model of hemorrhagic shock.

Authors:  Mona Soliman
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.